Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
NCT04835324 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 650
Last updated 2022-03-11
Summary
This is a multi-center, retrospective, real-world study. The purpose of this study is to observe the effectiveness and safety of regorafenib in Chinese advanced colorectal cancer patients.
The main observational goals include overall survival(OS), 6 month OS rate, 1 year OS rate, and treatment time failure (TTF), other study goals include objective response rate( ORR)、Disease control rate(DCR)and adverse event(AE) of regorafenib.
Conditions
- Advanced Colorectal Cancer
Sponsors & Collaborators
-
Beijing Hospital
collaborator OTHER_GOV -
Jiangsu Cancer Institute & Hospital
collaborator OTHER -
The Affiliated Hospital of Qingdao University
collaborator OTHER -
Shanxi Province Cancer Hospital
collaborator OTHER -
Affiliated Hospital of Hebei University
collaborator OTHER -
Shandong Cancer Hospital and Institute
collaborator OTHER -
The First Affiliated Hospital of Zhengzhou University
collaborator OTHER -
Hebei Medical University Fourth Hospital
collaborator OTHER -
First Hospital of China Medical University
collaborator OTHER -
Chinese Academy of Medical Sciences
lead OTHER
Principal Investigators
-
Yunbo Zhao · Beijing Hospital
-
Liangjun Zhu · Jiangsu Cancer Institute & Hospital
-
Zimin Liu · The Affiliated Hospital of Qingdao University
-
Wei Bai · Shaanxi Provincial Cancer Hospital
-
Aimin Zang · Affiliated Hospital of Hebei University
-
Bo Liu · Shandong Cancer Hospital and Institute
-
Hong Zong · The First Affiliated Hospital of Zhengzhou University
-
Shengmian Li · The fourth hospital of Hebei medical university and hebei cancer hospital
-
Xiujuan Qu · First Hospital of China Medical University
-
Aiping Zhou · Cancer Hospital Chinese Academy of Medical Science
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-01
- Primary Completion
- 2022-02-01
- Completion
- 2022-10-01
Countries
- China
Study Locations
More Related Trials
-
Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer
NCT01129700 ·Status: COMPLETED ·Phase: PHASE2
-
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052 ·Status: NOT_YET_RECRUITING
-
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
NCT01523431 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
NCT02688023 ·Status: UNKNOWN ·Phase: PHASE2
-
Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer
NCT06114420 ·Status: RECRUITING
-
FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World Study
NCT02887313 ·Status: UNKNOWN ·Phase: PHASE2
-
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
NCT06835179 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety Study of Neoadjuvant in Treating Patients With Resectable Local Recurrent Rectal Cancer
NCT01271192 ·Status: UNKNOWN ·Phase: NA
-
FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer
NCT03161574 ·Status: WITHDRAWN ·Phase: PHASE2
-
High Dose Radiotherapy for the Treatment of Rectal Cancer
NCT03541304 ·Status: COMPLETED
-
An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer
NCT04443543 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
NCT05371197 ·Status: UNKNOWN ·Phase: PHASE2
-
Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
NCT06314737 ·Status: COMPLETED
-
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
NCT05571644 ·Status: RECRUITING ·Phase: PHASE2
-
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
NCT05635149 ·Status: UNKNOWN
-
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
NCT06027775 ·Status: COMPLETED
-
Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer
NCT01671891 ·Status: UNKNOWN
-
Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer
NCT02071069 ·Status: UNKNOWN ·Phase: PHASE2
-
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
NCT05640726 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Maintenance Treatment With Capecitabine in Colorectal Cancer Patients
NCT02027363 ·Status: UNKNOWN ·Phase: PHASE2
-
Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer
NCT06040021 ·Status: COMPLETED
-
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
NCT06356714 ·Status: RECRUITING ·Phase: PHASE2
-
Exploratory Study of Intermittent Hypoxia Intervention on Colorectal Cancer
NCT06584318 ·Status: RECRUITING ·Phase: NA
-
SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer
NCT06908031 ·Status: RECRUITING ·Phase: PHASE2
-
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
NCT03426371 ·Status: TERMINATED ·Phase: PHASE3